COUR Nanoparticle Platform (CNP) is a nanoparticle designed to be taken up in the spleen and liver. CNP-103 aims to prevent islet cell destruction by T cells, which allows for maintenance of insulin production. Previous studies on CNP have been done for other autoimmune diseases like Celiac.

The main purpose of this study is to see how safe and tolerable CNP-103 is for people with type 1 diabetes. Study medication or placebo will be administered via IV infusion and participants will be on site for 8-10 hours.

Key inclusion criteria:

• Men and non-pregnant, non-breast-feeding women ages 12-35 years inclusive.
• Documented diagnosis of T1D within 180 days prior to study enrollment according to at least 1 of the ADA criteria.
• Participants must be on standard of care diabetes management (e.g., insulin therapy, a nutrition plan, regular exercise, or other relevant specialty care).
• Participants with a peak stimulated C-peptide of >0.2 nmol/L measured from a MMTT.
• NOTE: this test result may be obtained from an MMTT conducted within 1 month of planned first dose.